Dr Benjamin Mullish Honorary consultant in hepatology
- Patient age group
- Adults
- Consultant registered on
- 05/08/2008
- Primary medical qualifications
- MB BChir
- Gender
- Male
- Services
- Hospitals
Contact
- Phone
- 020 3312 6254
Hepatology administration team
Background
Dr Benjamin Mullish is a consultant hepatologist based mostly at St Mary’s Hospital, London, where he has specialist clinical expertise in fatty liver diseases, chronic liver disease, and general hepatology. He also performs endoscopy. In addition, he has a particular clinical and research interest in the contribution of the gut microbiome to improve health (including via faecal microbiota transplant (FMT)). In his day-to-day role, he contributes to the specialist regional clinic for metabolic dysfunction-related steatotic liver disease (MASLD). He is also a research fellow in the division of digestive diseases at Imperial College London, where he plays an integral role in an active research group investigating the gut microbiome, performing both laboratory work related to this, as well as undertaking clinical trials for a variety of medical conditions. He is co-director of the Imperial FMT service. He has contributed to a range of consensus documents and guidelines related to microbiome diagnostics and therapeutics.
Benjamin graduated in Medicine from the University of Cambridge with Double First Class Honours and a Foundation Scholarship, before undertaking combined clinical and academic training in gastroenterology, hepatology and general internal medicine in London. During his training, he obtained a PhD from Imperial College London for research related to the mechanisms by which FMT (and other therapies related to the gut microbiome) provide their benefit. He has obtained competitive research fellowships and research grants from the Medical Research Council.
Benjamin has been awarded a number of national and international prizes, including the British Society of Gastroenterology Young Gastroenterologist of the Year Award, and the United European Gastroenterology ‘Rising Star’ Award. He has co-authored more than 150 peer-reviewed publications, and regularly presents his research at leading medical conferences. He also contributes to both undergraduate and graduate teaching programmes at Imperial College London.
Expertise
Hepatology; liver diseases; metabolic dysfunction-associated steatotic liver disease; alcohol-associated liver disease; cirrhosis; FibroScan; C. difficile infection
Research & publications
Porcari S., Mullish B.H., Asnicar F., et al. International consensus statement on microbiome testing in clinical practice. Lancet Gastroenterology and Hepatology (2025);10(2):154-167, doi: https://doi.org/10.1016/S2468-1253(24)00311-X.
Mullish B.H., Thursz M.R. Alcohol-associated liver disease: emerging therapeutic strategies. Hepatology (2024);80(6):1372-1389, doi: 10.1097/HEP.0000000000000986.
Mullish B.H., Merrick B., Quraishi M.N., et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut (2024);73(7):1052-1075, doi: 10.1136/gutjnl-2023-331550.
Forlano R., Martinez-Gili L., Takis P..., Mullish B.H., Manousou P. Disruption of gut barrier integrity and host-microbiome interactions underlying MASLD severity in patients with type-2 diabetes mellitus. Gut Microbes (2024);16(1):2304157, doi: 10.1080/19490976.2024.2304157.
Routy B., Lenehan J.G., Miller J W.H..., Mullish B.H., Silverman M.S., Burton J.P., Maleki Vareki S. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nature Medicine (2023);29(8):2121-2132, doi: 10.1038/s41591-023-02453-x.